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Abstract 
Malaria is responsible for over 1,000 deaths every day across the globe. Young children are 
particularly at risk, making malaria one of the top causes of death for children in the world.  
Despite this toll on human life, the treatment of malaria has historically not been a priority in 
the pharmaceutical world. This review focuses the treatment of malaria from a pharmacologic 
perspective. It provides guidance for the prevention and treatment of malaria according to CDC 
and WHO recommendations. Information was gathered using current guidelines, retrospective 
and prospective clinical trials, systematic reviews, and drug references. There are five species of 
Anopheles mosquitoes that are responsible for the transmission of malaria, with P. falciparum 
being the deadliest. The treatment of the disease depends on the responsible species. In 








Malaria is a protozoan disease transmitted by the Anopheles mosquito.1 In the genus 
Plasmodium, there are six species that are primarily responsible for malaria transmission.1  
These include Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale (further divided 
into two subtypes), Plasmodium malariae, and Plasmodium knowlesi.1,2 Malaria occurs in most 
tropical regions throughout the world and is transmitted in 91 countries (See Figure 1).3 
Although malaria is not endemic to the United States, there are still approximately 1,700 cases 
reported annually due to increasing world travel.3 About 10% of these cases are severe.3  
 
 
Figure 1: Malaria global transmission3 
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Children under the age of five years old are the most at risk to development of malaria and to 
complications, including death.1 This disease is responsible for about 1200 deaths each day.1 
Over the past 15 years, there has been a promising trend of lower death rates due to better 
control programs, but that progress has plateaued the last several years.  
 
P. falciparum is the deadliest and occurs primarily in Africa, New Guinea, and Hispaniola. P. 
vivax occurs mostly in Central America, South America, and China; P. ovale in Africa; P. malariae 
in most endemic regions; and P. knowlesi in Borneo.1,2 In areas where malaria is holoendemic 
and hyperendemic with high P. falciparum transmission (this includes areas of tropical Africa or 
coastal New Guinea) it is estimated that people may receive as many as one infectious 




The transmission of malaria to a human begins with the bite of an infected mosquito. Upon the 
bite, plasmodial sporozites are injected from the salivary gland into the bloodstream.1 The 
sporozites specifically attack hepatic parenchymal cells.1 It is here where the asexual 
reproduction cycle begins.1 Eventually the cells become overwhelmed by the reproduction, 
swell, and burst, expelling merozites into the bloodstream.1 Merozite then invade erythrocytes, 
at which point they are referred to as trophozites.1 Here they begin contributing to the 
symptomology seen in malaria.2  
 
Patients typically become symptomatic at a load of about 100 million trophozites.1 In some 
species, such as P. knowlesi and P. malariae, the load can reach 100 million in 2-3 days.1 
Contrarily, in P. vivax and P. ovale, the sporozites can remain dormant from anywhere between 
two weeks to longer than 1 year.1,2 These sporozites remain intrahepatic and stay dormant, 
earning them the name “hypnozites.”1 It is this form that is responsible for high relapse rates in 
in P. vivax and P. ovale.1 
 
Within the erythrocyte, trophozites are responsible for the degradation of various intracellular 
proteins, especially hemoglobin.1 This degraded hemoglobin is converted to hemozoin.1 The 
initial host response to this protozoan attack is non-specific; monocytes and macrophages are 





Due to the indiscriminate initial immune response, the first symptoms of malaria are relatively 
non-specific.4 They include fever, headache, fatigue abdominal pain, myalgias, nausea, 
vomiting, and orthostatic hypotension.1,4 Fever is an important characteristic in initial 
presentation. Uncomplicated infections typically present rather benign, with symptoms such as 
fever, malaise, mild anemia, and occasionally splenomegaly.1,4 Because of this vague 
presentation, in regions where malaria is not endemic, such as the United States, malaria is 
commonly misdiagnosed.4   
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More severe infections occur with infections from P. falciparum. They can also develop from 
infection with other species, but the likelihood is much lower. In order to be classified as 
severe, patients must present with one or more of the following: 
 
Table 1: Symptoms of severe malaria1 
Jaundice Hypotension/shock 
Acidosis Acute respiratory distress syndrome 
Severe anemia Bleeding/disseminated intravascular coagulation 
Renal failure Extreme weakness 
Pulmonary edema Cerebral malaria (unarousable coma) 
Hypoglycemia Severe normocytic anemia (hemoglobin <7) 
Convulsions Parasitemia of ≥5% 
Hemoglobinuria  
 
Determining the severity of a patient’s malaria is critical in selecting the appropriate 




There are several methods of diagnosis for malaria. The gold standard is through an immediate 
blood smear with microscopy. However, this is not always possible due to lack of equipment 
and/or proper training. When microscopy is not available, the rapid test is an adequate option. 
The downside to this test is that is cannot determine the infecting species. PCR testing is 
another option, which is the most sensitive, but it is not used in the clinical setting.1,4 
 
People infected with malaria can be symptomatic even at very low parasite densities. Because 
of this, it is necessary to repeat blood smears every 12 to 24 hours for a total of three sets. The 
parasite density may not be detectable early on when it is still too low. Three negative tests are 




Goals of Therapy 
 
The initial goal of malaria treatment is determining and initiating effective, targeted therapy.5 
Ideally, therapy should be chosen to prevent resistance through the selective use of 
antimalarials.5  
 
The ultimate goal in the treatment of malaria is the eradication of the disease throughout the 
world. The World Health Organization (WHO) has created a goal, the E-2020 initiative, that aims 
to achieve zero cases of malaria in 21 select countries by 2020.5 Paraguay and Uzbekistan have 
already been certified malaria free since 2018.5 Nine countries are currently classified as “on 
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track,” five countries are classified as “slightly off track,” and five are classified as “off track.”5 
While the goal is lofty and progress is not perfect, it is indeed encouraging that 11 countries are 
currently or are headed to being malaria free.  
 
Therapy: Prevention and Nonpharmacologic Options 
 
Logically, the best way to prevent malaria is to prevent the bite from a carrying mosquito. 
Simple avoidance strategies can be employed to decrease the chances of transmission to 
humans. If possible, people living in or traveling to endemic areas should avoid exposure to 
mosquitoes at peak feeding time, which is from dusk to dawn.1 Insect repellent with 10 to 35% 
DEET should be used to prevent bites, as well as wearing protective clothing and utilizing 




Seasonal malaria chemoprevention should be implemented when possible to people living in 
high transmission areas. Priority should be given to high risk groups, including pregnant women 
and young kids.1,2 The choice of prophylactic medication depends on the local patterns of 
sensitivity and the typical Plasmodium species in the area.1 If the species is unknown, it is 
important to cover against P. falciparum.2 When traveling to endemic areas, it is recommended 
that people begin antimalarial prophylaxis therapy two days to two weeks prior to arrival, 
depending on the specific drug treatment (See Table 2).1,6 With most agents, prophylaxis is then 
continued for four weeks after leaving the endemic area.1,6  
 
Largely, the prophylactic choice will be determined by location. The Centers for Disease Control 
and Prevention website offers a helpful tool to healthcare providers in selecting the most 
appropriate option and regimen based on geographic location. 
 
As a guide, some general options are outlines in Table 2. Notice the duration of treatment for 
each option. Atovaquone and primaquine are exceptions to the rule of treating for four weeks 
after travel as they are only required to be continued for seven days after travel ends.6 Many of 
the treatment options for malaria can be dosed in the base form or salt form. This is an 
important detail for pharmacists to pay attention to as there is a higher chance for dosing 
errors between these different forms. Each pharmacotherapy option will be discussed in 
further detail under “Pharmacology of Discussed Drugs.”  
 
Table 2: Prophylactic pharmacotherapy options1,6 
 Adult Dose Specific Indication  
Atovaquone-proguanil 
(Malarone) 
250/100 mg PO once daily starting 
2 days before travel; continue for 7 
days after 
In areas with chloroquine or 
mefloquine resistant P. 
falciparum- effective against 
all species 
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Chloroquine 300 mg of base (500 mg salt) PO 
once weekly; start 2 weeks before; 
continue for 4 weeks after 
Chloroquine-sensitive P. 
falciparum or P. vivax 
Doxycycline 100 mg PO qd; start 2 days before; 
4 weeks after 
Chloroquine or mefloquine 
resistant P. falciparum 
Hydroxychloroquine 
sulfate 
310 mg of base (400 mg salt) PO 
once weekly; start 1-2 weeks 
before; continue for 4 weeks after  
Alternative to chloroquine  
Mefloquine  228 mg base (250 mg salt) PO once 
weekly; start 1-2 weeks before; 
continue for 4 weeks after  
Chloroquine resistant P. 
falciparum 
Primaquine 30 mg base (52.6 mg salt) PO once 
daily; start 1-2 days before; 
continue for 7 days 
Primarily for P. vivax and for 
anti-relapse therapy 
(terminal prophylaxis) in P. 
vivax and P. ovale  
 
 
Therapy: Prevention through Vaccination 
 
Within the last decade, further development has taken place on the possibility of a malaria 
vaccine. RTS,S/AS01 is a new malaria vaccine that acts against P. falciparum. A vaccine against 
this species has the possibility to prevent countless cases of malaria and hundreds of thousands 
of deaths every year.7,8 The initial results from phase III clinical trials of RTS,S/AS01 showed 
promising results.8 A trial conducted from 2009 to 2014 showed the following results:  
 
 
Figure 2: Results of efficacy of malaria vaccine,8 
 
After such substantial results, new implementation efforts started throughout Africa.8 Now five 
years after these initial results, more data is coming forward that raises questions about the 
long-term efficacy of this vaccine.7 A retrospective study, “Seven-Year Efficacy of RTS,S/AS01 
Malaria vaccines among Young African Children," reviewed the long term efficacy of 
RTS,S/AS01.7 The children in the study population were included in the initial trial that looked at 
results at baseline, 1 month, and 2 months, but the long-term study then followed subjects 




The primary outcome measured in the study was clinical malaria from P. falciparum.7 The 
efficacy in the first year was 35.9%, compared to 3.6% in the seventh year.7 What is of 
particular interest is the differences in malaria cases based on the exposure index between 
groups. The study population was divided in a high exposure index and a low exposure index. In 
the low-exposure group, cases of malaria were overall averted in the seven-year period.7 In the 
high-exposure group, there were negative cases averted overtime.7 Per 1000 participants, it 
was measured that there were 141 more cases in those who received the vaccine versus those 
who did not.7 This potential for rebound is concerning in high-exposure groups.  
 
It is postulated that the rebound may occur based on the way the RTS,S/AS01 vaccine alters 
immunity. It covers against malaria sporozites but does not create immunity against blood-
stage parasites.7 In children who received the vaccine, the acquisition of immunity to blood-
stage parasites is likely slower, thus increasing the likelihood of clinical malaria years later.7 In 
high-transmission areas, the waning efficacy later in life may outweigh the benefits of the 
RTS,S/AS01 vaccination early on.7 While there is still promise with such vaccination methods, 
the overall benefit on malaria transmission and public health is far from optimal.  
 
Therapy: Treatment in the United States as Recommended by the CDC 
 
The Centers for Disease Control and Prevention (CDC) outline treatment guidelines for patients 
in the United States. There are three main factors that dictate the course of therapy: 
1. The Plasmodium species 
2. The patient’s clinical status 
3. Drug susceptibility  
 
Plasmodium Species 
Depending on the Plasmodium species, the progression of malaria is likely to vary. Recall 
that P. falciparum typically causes the most severe infections.1,9 Likewise, P. knowlesi can 
also rapidly progress to severe cases.9 Relapse is common in P. vivax and P. ovale due to the 
dormant hypnozites that remain in the liver.1,9 It is also important to realize that P. 
falciparum and P. knowlesi are more likely to have geographic drug resistance patterns.1,9  
 
Clinical Status 
A critical factor in determining the course of treatment is the status of the patient upon 
presentation (whether they are uncomplicated or severe) or whether they develop severe 
malaria while receiving treatment.9 Cases of uncomplicated malaria are treated with oral 
antimalarials.9 If the patient present with one or more the symptoms to classify as severe, 
the patient must be treated aggressively with parenteral antimalarials.9  
 
Drug Susceptibility of Parasite 
Depending on where a patient contracted a case of malaria, the geographic region guides 
the susceptibility patterns.9,10 Some areas are much more prone to resistance and cases 
from such areas need to be treated more aggressively and monitored for resistance.9,10 It is 
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also imperative to know if malaria occurred despite the use of chemoprophylaxis, as that 
agent should not be use in the pharmacotherapy to treat the patient.9  
 
The CDC’s guideline for treating malaria is outlined as follows: 
 
- Uncomplicated Malaria 
o P. falciparum or unknown species (in species WITH chloroquine resistance) 
o P. falciparum or unknown species (in species WITHOUT chloroquine resistance) 
o P. malariae and P. knowlesi 
o P. vivax and P. ovale  
o Alternatives in pregnancy  
- Complicated Malaria 
 
All treatment regimens discussed in this review are dosed for a typically adult patient. Similar 
treatment guidelines can be followed when treating pediatric patients, but dosing will be 
altered.  
 
Treating P. falciparum or unknown species (in species WITH chloroquine resistance)9 
In patients with confirmed chloroquine resistance, treat with one of the options in Table 3. It is 
critical to note that resistance is often unknown at the time of diagnosis. Antimalarial drug 
susceptibility testing can be performed but is not often used. This is because it is rarely 
available in most locations, it has poor predictive value in an individual case, and it is too slow 
to be clinically relevant. If there are any questions about the possibility of resistance, it is the 
best practice to assume resistance and cover for that infecting organism. 
 
Table 3: Treating P. falciparum or unknown species (in species WITH chloroquine resistance)9 
Recommended Drug Recommended Adult Doses and Duration 
Atovaquone-proguanil 
(Malarone) 
250 mg/100 mg tablets 
4 tabs PO QD x 3 days 
Artemether-lumefantrine 
(Coartem) 
20 mg/120 mg tablets 
4 tabs PO initial dose, 4 tabs 8 hours later, then 4 tabs BID x 
2 days 
Quinine sulfate plus 1 of: 
• Doxycycline 
• Tetracycline 
• Clindamycin  
Quinine: 542 mg base (650 mg salt) PO TID x 3 days  
• Doxycycline: 100 mg PO BID x 7 days 
• Tetracycline 250 mg PO QID x 7 days 
• Clindamycin 20 mg base/kg/day PO divided TID x 7 
days 
Mefloquine (Lariam)  684 mg base (750 mg salt) PO initial dose, then 456 mg base 




The CDC does not recommend one option over the other between atovaquone-proguanil, 
artemether-lumefantrine, and quinine in combination with an antibiotic. From the options 
above, mefloquine if the least preferred as there is less robust data supporting its use. Among 
the antibiotics used in combination with quinine, studies favor either doxycycline or 
tetracycline in preference over clindamycin.  
 
Treating P. falciparum or unknown species (in species WITHOUT chloroquine resistance)9 
In patients without chloroquine resistance, any of the above treatment options outlined in 
Table 3 can appropriately be used based on availability. While it is ideal to choose the most 
selective option to decrease resistance patterns, it is most important to initiate therapy quickly, 
so any effective regimen readily at hand is appropriate. Other options that can be used in 
patients without chloroquine resistance are listed in Table 4.  
 
Table 4: Treating P. falciparum or unknown species (in species WITHOUT chloroquine resistance)9 
Recommended Drug Recommended Adult Doses and Duration 
Chloroquine phosphate 
(Aralen)  
600 mg base (1,000 mg salt) PO immediately, then 300 mg base 
(500 mg salt) at 6, 24, and 48 hours 
Hydroxychloroquine 
(Plaquenil)  
620 mg base (800 mg salt) PO immediately, then 310 mg base 
(400 mg salt) at 6, 24, and 48 hours  
Any regimen used for 
chloroquine-resistance 
malaria is also 
recommended 
Quick initiation is key, so any effective regimen readily at hand is 
appropriate 
 
Treating P. malariae and P. knowlesi9 
When treating P. malariae and P. knowlesi, utilize an option in Table 5.  
 
Table 5: Treating P. malariae and P. knowlesi9 
Recommended Drug Recommended Adult Doses and Duration 
Chloroquine phosphate 
(Aralen)  
600 mg base (1,000 mg salt) PO immediately, then 300 mg base 
(500 mg salt) at 6, 24, and 48 hours 
Hydroxychloroquine 
(Plaquenil)  
620 mg base (800 mg salt) PO immediately, then 310 mg base 
(400 mg salt) at 6, 24, and 48 hours  
 
Treating P. vivax and P. ovale9 
For patients with P. vivax and P. ovale, a longer duration of treatment is required. Due to the 
possibility of dormant hypnozites causing relapsing infections, primaquine treatment for 14 
days is included in all treatment regimens. This increases the likelihood of effectively removing 
the hypnozites, decreasing relapse rates. See Table 6. 
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Table 6: Treating P. vivax and P. ovale9 




• Chloroquine: 600 mg base (1,000 mg salt) PO 
immediately, then 300 mg base (500 mg salt) at 6, 24, 
and 48 hours 
• Primaquine: 30 mg base PO QD x 14 days 
Hydroxychloroquine PLUS 
primaquine phosphate 
• Hydroxychloroquine: 620 mg base (800 mg salt) PO 
immediately, then 310 mg base (400 mg salt) at 6, 24, 
and 48 hours  
• Primaquine: 30 mg base PO QD x 14 days 
 
 
Treating Chloroquine-Resistant P. vivax9 
Chloroquine resistance P. vivax is becoming more prevelant in regions throughout Papua New 
Guinea and Indonesia. Use a treatment option for Table 7 for effective therapy. 
 
Table 7: Treating Chloroquine-Resistant P. vivax9 
Recommended Drug Recommended Adult Doses and Duration 
Quinine sulfate PLUS primaquine 
phosphate PLUS either 
doxycycline or tetracycline 
• Quinine: 542 mg base (650 mg salt) PO TID x 3 
days  
• Primaquine: 30 mg base PO QD x 14 days 
o Doxycycline: 100 mg PO BID x 7 days 
o Tetracycline 250 mg PO QID x 7 days  
Atovaquone-proguanil PLUS 
primaquine phosphate  
• Atovaquone-proguanil: 250 mg/100 mg tablets; 4 
tabs PO QD x 3 days 
• Primaquine: 30 mg base PO QD x 14 days  
Mefloquine PLUS primaquine 
phosphate 
• 684 mg base (750 mg salt) PO initial dose, then 
456 mg base (500 mg salt) 6-12 hours after 




Treating Malaria in Pregnancy6,9 
Pregnancy is a critical time to ensure proper treatment as the risk for infection to the fetus is 
high. There are several available treatments that are safe in pregnancy.  
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Table 8: Treating Malaria in Pregnancy 
Recommended Drug Pregnancy Considerations 
Chloroquine Sensitive 
Chloroquine phosphate Can be used in all trimesters 
Hydroxychloroquine Alternative option  
Chloroquine Resistant  
Artemether-lumefantrine (Coartem) Can be used in second or third trimester 
Quinine sulfate PLUS clindamycin Can be used in all trimesters 
Mefloquine Can be used in all trimesters 
 
Treating Severe/Complicated Malaria 
It is recommended that all cases of severe malaria be treated with rapid initiation of parenteral 
antimalarials.9 Table 9 outlines appropriate quinidine-based treatment options. Once the 
parasite density is <1% and once the patient can tolerate oral therapy, it is appropriate to 
switch to oral quinidine and an oral antibiotic and complete the course of quinidine for three to 
seven days.9  
 
Table 9: Treating Severe/Complicated Malaria9 
Recommended Drug Recommended Adult Doses and Duration 
Quinidine gluconate 
PLUS ONE of following: 
6.25 mg base (10 mg salt)/kg ABW IV loading dose over 1-2 
hours then 0.0125 mg base/kg/min continuous infusion for at 
least 24 hours 
• Doxycycline  PO: 100 mg PO BID  
IV: 100 mg IV Q 12 hours until PO tolerated 
• Tetracycline  PO: 250 mg PO QID  
• Clindamycin PO: 20 mg base/kg/day PO divided TID  
IV: 10 mg base/kg IV loading dose then 5 mg base/kg IV every 8 
hours until PO tolerated  
 
The other treatment option recommended by the CDC for severe malaria is artesunate followed 
by one of the following: atovaquone-proguanil, doxycycline, or mefloquine.9 This type of 
combination therapy is referred to as artemisinin-based combination therapy (ACT).2 
Artesunate is an artemisinin derivative.6 This pharmacologic treatment has been used in other 
countries for years, but in the United States it is classified as an investigational new drug.2,9 It is 
only available in the U.S. through special request to the CDC Drug Service or Quarantine 
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Station.9 This does delay time to treatment. Additionally, artesunate is only available in 
intravenous formulations in the U.S., but in other countries it is available in other formulations.9  
 
Recall from the “Treating P. falciparum or unknown species (in species WITH chloroquine 
resistance)” that artemether is another treatment option recommended by the CDC, and this 
too is an artemisinin derivate.1,9 However, artesunate is shown to have a higher survival benefit 
over artemether in severe malaria, which is why this is the preferred option in severe cases.11 
 
Pharmacology of Discussed Drugs 
 
Artemether-lumefantrine2,6 
Artemether, an artemisinin derivative, exerts its effect broadly on blood-stage parasites. 
Lumefantrine works by preventing detoxification within parasites. Caution must be used in 
patients with meningitis and renal failure. Overall, this treatment is well tolerated; it may cause 
some nausea, dizziness, headache, and palpitations. Artemether-lumefantrine can prolong the 
QT interval and the likelihood of this is increased when used with other QT prolonging agents. 
Artemether-lumefantrine interacts with medications metabolized by CYP3A4 as it is a strong 
inducer of this enzyme.  
 
Artesunate2,6 
Artesunate is a prodrug that is converted to dihydroartemisinin, which then is active against all 
erythrocytic stages of the parasite. It inhibits the metabolism of parasites and increases 
clearance of the infected erythrocytes. Use caution in patients with anemia, renal impairment, 
and hepatic impairment. Overall artesunate is well tolerated. It may cause some 
gastrointestinal upset, cough, rash, arthralgia, dizziness, or delayed hemolysis. There are also 
relatively few notable drug interactions.  
 
Atovaquone-proguanil2,6 
Atovaquone works by inhibiting parasitic enzymes and the electron transport process within 
the parasite. Proguanil inhibits dihydrofolate reductase. Monitoring parameters to be aware of 
include monitoring renal and hepatic function. Use caution when treating elderly patients and 
patients who weigh greater than 100 kg. Overall, atovaquone-proguanil is well tolerated. The 
more common adverse effects are relatively mild and include headache, cough and 
gastrointestinal upset. Rare adverse effects include oral ulceration, blood dyscrasias, and 
photosensitivity. There are not many significant drug interactions to be aware of besides 




The mechanism of action of chloroquine is the prevention of detoxification within the parasite 
and interference with nucleic acid synthesis. Caution should be used in patients with psoriasis, 
neurological disorders, and hepatic impairment. Acute overdose can occur with chloroquine 
and in extreme cases lead to convulsions, hypokalemia, and death. A common adverse effect of 
chloroquine is pruritis. More rare adverse effects are headache, hepatitis, gastrointestinal 
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disturbances, and retinal damage. Chloroquine can also contribute to slight widening of the QT 
interval. Chloroquine participates in numerous drug interactions; it is a major substrate of both 
CYP2D6 and CYP3A4. 
 
Hydroxychloroquine2,6 
Hydroxychloroquine disrupts parasite function by increasing the pH and interfering with the 
degradation of hemoglobin. Monitoring parameters include complete blood count, renal and 
hepatic function, and an eye exam. Caution must be executed in patients with retinal diseases, 
cardiac arrhythmias, hematologic disorders, neuromuscular disorders, and G6PD deficiency. 
There are many adverse effects associated with hydroxychloroquine use. Common ones include 
nausea, vomiting, diarrhea, dizziness, headache, and rash. More severe adverse effects are 
myopathy, weakness and atrophy, hemolysis, seizure, and hypoglycemia. Hydroxychloroquine 
can prolong the QTc interval so it must be used with caution when given with other QT 
prolonging agents. Due to the hypoglycemia associated with use, hydroxychloroquine is also 
noted to interact with antidiabetic agents.  
 
Mefloquine2,6 
The exact mechanism of action of mefloquine is uncertain. It likely works by preventing 
parasitic detoxification. When initiating therapy with mefloquine, caution must be given in 
hepatic impairment. It is contraindicated for prophylaxis in patients with psychiatric disorders, 
including depression. This is because mefloquine carries a boxed warning for neuropsychiatric 
effects. It has more central nervous system and gastrointestinal issues than other options. 
When used with rifampin, mefloquine is rapidly eliminated. 
 
Primaquine2,6 
Primaquine is active against hypnozoites and gametocytes. It works by disrupting the 
mitochondrial metabolism. Primaquine use must include monitoring of the complete blood 
count for hemolysis. Hemolysis is possible is patients with G6PD deficiency and is 
contraindicated in this population. Gastrointestinal discomfort is a common adverse effect, and 
more rare adverse effects include hypotension and arrhythmias. Although primaquine is a 
major substrate of CYP2D6 and CYP 3A4, there are few clinically relevant drug-interactions. 
 
Quinine2,6 
Quinine’s mechanism of action works by directly attacking asexual parasites and disrupting the 
oxygen uptake and carbohydrate metabolism. Use caution when using in patients with 
arrhythmias, heart disease, hepatic disease, and renal disease. Monitoring of the QT interval 
must be done. QT prolongation is a possible severe adverse effect. Other severe complications 
include vertigo, diarrhea, auditory and visual loss, and hypoglycemia. More mild adverse effects 
include tinnitus, headache, nausea, dizziness, dysphoria, and visual disturbances. There are 
many possible adverse effects associated with quinine use, and because of this, the collection 
of side effects is referred to as “cinchonism.” Major drug interactions with quinine include 





Quinidine works through the breakdown of hemoglobin in the parasites. It has many serious 
adverse effects and drug interactions. Due to these many complications, telemetry is required 
when administering to a patient. Renal and hepatic function must also be monitored. Quinidine 
is contraindicated in thrombocytopenia and any degree of heart block greater than first degree. 
Adverse effects include diarrhea, gastrointestinal distress, dizziness, palpitations, headache, 
hepatotoxicity, and hemolysis with G6PD deficiency. Quinidine is a major substrate of CYP3A4, 
a strong inhibitor or CYP2D6, and also inhibits CYP3A4 and P-glycoprotein, leading to many drug 
interactions. Quinidine is also contraindicated with digoxin and other antiarrhythmics. 
 
Therapy:  Treatment Recommendations from the WHO 
 
The World Health Organization malaria treatment guidelines depend much more on 
artemisinin-based combination therapy (ACT) than those of the CDC. Because ACT utilize the 
combination of medications with different mechanisms, there is a decreased risk for resistance 
when treating malaria.2 The following is a summary of the WHO treatment guidelines: 
 
Table 10: WHO Malaria Treatment2 
WHO Malaria Treatment Guidelines 
Uncomplicated P. falciparum 
       Use of an artemisinin-based combination therapy (ACT) for 3 days 
Uncomplicated P. vivax, P. ovale, P. malariae, or P. knowlesi 
       Chloroquine susceptible: ACT or chloroquine 
       Chloroquine resistant: ACT 
Severe malaria 




CDC vs. WHO: A Difference in Guidelines 
 
Based on the efficacy and safety of artesunate, it clearly seems a superior choice for the 
treatment of malaria. Artemisinin-based combination therapy provides effective treatment and 
lower rates of resistance.2 The WHO is more progressive in terms of utilization of ACT, but the 
CDC guidelines are still appropriate for the population it is treating. Artesunate is available to 
patients in the United States, and while less than 2,000 cases occur within the United States, it 









Once a case of malaria has been confirmed and treatment has begun, patients must have the 
parasitological status monitored. It recommended that monitoring continue at least 28 days 
after starting treatment for the reappearance of parasites.2,9 This is especially critical with 
infections from P. vivax and P. ovale due to the higher rates of recurrence in these species.2,9 
Blood smears should be completed in infections with P. falciparum as well as cases of suspected 
chloroquine-resistant P. vivax, as it is difficult to assess therapeutic response due to relapse.2 
 
Surveillance and Resistance 
 
The WHO recommends routine surveillance with the “test, treat, track” initiative.2 This outlines 
that to “test” every case of suspected malaria, “treat” every confirmed case with quality 
assured treatment, and “track” the disease with timely and accurate surveillance.2 All cases of 
resistance should be documented, regardless of the class of antimalarial drug.2 It is important 
to remember that resistance is slowed by the use of combination antimalarial therapies.2 
Patients must also be educated on the importance of adherence to the medication regimen in 
order to decrease the emergence of resistance.2 
 




Malaria is responsible for killing one person every minute.12 Over one million people die every 
year from malaria and an estimated 300-600 million suffer from a malaria infection each year.12 
Almost half of the global population lives in malaria-endemic areas.13 Over the past decade, the 
global burden of malaria seemed to be decreasing.14 There were 239 million cases in 2010, 
which decreased to 214 million in 2015.14 It seems this progress has leveled off the past several 
years, with 219 million cases of malaria in 2017 and 217 million in 2016.14  
 
According to the WHO general-director, “the world faces a new reality: as progress stagnates, 
we are at risk of squandering years of toil, investment and success in reducing the number of 
people suffering from the disease.”14 Due to the stagnation shown in the World Malaria Report 
2018, the WHO is initiating a new action plan; a country-focused and country-led plan to take 
action against malaria at the local level.14  
 
There have been increases in recent years in the use of insecticide-treated bed nets in sub-
Saharan Africa, but it is estimated that in 2017 half of the at-risk people in Africa did not sleep 
under such bed nets.14 Indoor residual spraying is another method to decrease malaria 
transmission within homes, but those efforts have actually decreased in recent years.14 
Additionally, access for high risk groups, such as pregnant women and young children, to 
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preventative therapy remains low.14 The WHO previously created an initiative called the “WHO 
Global Technical Strategy for Malaria 2016-2030,” which had the goal of reducing malaria cases 
and death rates by 40% by 2020.14 This goal is not on track to being met.  
 
Due to this reality, in November 2018 the World Health Organization launched a new strategic 
plan, the “High burden to high impact” response plan. Its four key components are to 
“galvanize national and global political attention to reduce malaria deaths; drive impact 
through the strategic use of information; establish the best global guidance, policies and 
strategies suitable for all malaria endemic countries; and implement a country coordinated 
response.”14 A large focus of this plan is on those countries that have the greatest disease 
burden form malaria. About 70% of all malaria cases and deaths come from 11 countries.14 
These are Burkina Faso, Cameroon, Democratic Republic of the Congo, Ghana, Mali, 
Mozambique, Niger, Nigeria, Uganda, the United Republic of Tanzania, and India.14 These 10 
African counties are sadly seeing rates of malaria on the rise, but India has fortunately shown a 
reduction in its disease burden in 2017.14  
 
In addition to India, where cases were reduced 24% in 2017, there are other bright spots in the 
fight against malaria. The E-2020 plan, as discussed previously, aims to certify 21 countries as 
malaria free by 2020.5 Besides Paraguay and Uzbekistan being certified malaria free, Algeria 
and Argentina are requesting to become certified malaria free as well.14 In addition, Rwanda, 




In correlation with the plateau of malaria cases, the funding for malaria has also leveled off in 
recent years. In 2017, $3.1 billion was allocated to malaria control and elimination.14 Of that 
sum, 39% ($1.2 billion) was contributed by the U.S., making them the largest international 
donor.14 Twenty-eight percent ($900 million) was contributed from governments of malaria 
endemic countries.14 The WHO estimates that in order to meet to 2030 goals for malaria 
control, there must be $6.6 billion available annually by 2020.14 The $3.1 million sum in 2017 is 
certainly a great investment, and it is hard to imagine doubling that figure by 2020.  
 
Why is there this gap in funding? What can be done about this unmet need? Bill Gates has 
famously declared capitalism as a flawed system: 
 
Our priorities are tilted by marketplace imperatives. The malaria vaccine in humanist 
terms is the biggest need. But it gets virtually no funding. But if you are working on male 
baldness or other things you get an order of magnitude more research funding because 
of the voice in the marketplace than something like malaria.13 
 
It is astonishing to consider that $2 billion is spent globally each year on surgical procedures for 
hair loss.13 While the latest numbers due show malaria has gained funding compared to hair 
loss, it is still astonishing to consider the prioritization of “lifestyle drugs.”  
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There is an unfortunate standard when it comes to global healthcare, referred to as the 10/90 
gap. This states that only 10% of the global healthcare expenditures on health research are 
dedicated to problems that affect 90% of the world population. In order to continue the 




The pharmacotherapy of malaria is continuing to advance with development of artemisinin-
based combination therapy. There are still untraversed gaps in the global healthcare system 
that lead to suboptimal prevention and prophylaxis, and ultimately result in an overwhelming 
disease burden of malaria. There is hope for the potential of an effective malaria vaccine. The 
RTS,S/AS01 vaccine shows some promise early on, but appears to have a waning effect in later 
years. It is imperative for funding to increase in order to meet the growing demands for 
effective vaccination, increased utilization of bed nets and insecticide treated bed nets, and the 
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